You are here: Industry Insights > Daiichi Sankyo

News List

Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer pharmaceutical-business-review
July 06, 2020
Daiichi Sankyo Company announced the first patient with triple negative breast cancer (TNBC) has been dosed in the ongoing phase 1 study assessing DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC).
Esperion, Daiichi Sankyo Europe Announce Amendment to License, Commercial Agreement americanpharmaceuticalreview
July 01, 2020
Esperion announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe (DSE).
Japan’s Daiichi Sankyo in talks with AstraZeneca for Covid-19 vaccine pharmaceutical-technology
June 28, 2020
Japanese pharmaceutical company Daiichi Sankyo has entered an agreement for discussions with AstraZeneca for the supply of a Covid-19 vaccine candidate, being developed in alliance with the University of Oxford, in Japan.
Thermo Fisher, Daiichi Sankyo to Co-Develop CDx contractpharma
June 24, 2020
Agreement aims to identify HER2 gene mutations using Oncomine Dx Target Test for patients with Non-Small Cell Lung Cancer.
Double digit MCap growth in 2019 for 14 of top 20 pharma companies: GlobalData expresspharma
June 19, 2020
Among the positive performances were Takeda Pharmaceutical and Daiichi Sankyo, which reported more than 100 per cent YoY growth in their market caps.
Daiichi Sankyo to develop Covid-19 vaccine candidate in Japan pharmaceutical-technology
June 16, 2020
Japanese pharmaceutical company Daiichi Sankyo is set to develop a mRNA vaccine candidate to protect against Covid-19 infection in the country.
Daiichi Sankyo to develop Nafamostat inhalation therapy for Covid-19 pharmaceutical-technology
June 10, 2020
Japanese pharmaceutical company Daiichi Sankyo has signed a basic agreement with the University of Tokyo, Nichi-Iko Pharmaceutical and RIKEN for the research and development (R&D) of a Nafamostat inhalation formulation to treat Covid-19.
AstraZeneca gets breakthrough status for Enhertu to treat NSCLC pharmaceutical-technology
May 20, 2020
AstraZeneca and its partner Daiichi Sankyo have received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for Enhertu (trastuzumab deruxtecan) to treat non-small cell lung cancer (NSCLC).
AZ/Daiichi Sankyo's Enhertu picks up third breakthrough designation pharmatimes
May 19, 2020
AstraZeneca's and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with a particular form of lung cancer.
AstraZeneca, Daiichi Sankyo get FDA breakthrough therapy status for gastric cancer drug pharmaceutical-business-review
May 12, 2020
AstraZeneca and Daiichi Sankyo have secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for its Enhertu.

Previous page 1 2 3 4 5 6 7 8 Next page